Cybin Secures U.S. Patent for CYB004 Program, Advancing Mental Health Treatment

Cybin, a clinical-stage neuropsychiatry company, has announced the issuance of U.S. patent 12,318,477, a milestone for its CYB004 program. This patent covers novel intramuscular formulations of DMT and related compounds, securing exclusivity for Cybin through 2040. The CYB004 program focuses on developing a deuterated DMT candidate aimed at treating generalized anxiety disorder (GAD), offering a promising rapid-acting, short-duration treatment option with a patient-friendly delivery method.

Doug Drysdale, CEO of Cybin, emphasized the patent as a validation of the CYB004 program's potential to revolutionize mental health treatment. Currently in Phase 2 trials, with completion expected by mid-2025, CYB004 represents a significant advancement in the field of psychedelic-based therapeutics. Cybin's portfolio now includes over 90 granted patents and more than 230 pending applications, underscoring the company's commitment to innovation in mental health care.

The implications of this patent extend beyond Cybin, signaling a broader shift in the acceptance and development of psychedelic-based treatments for mental health conditions. As the industry continues to evolve, Cybin's progress with CYB004 could pave the way for new, effective treatments for GAD and other mental health disorders, addressing a significant unmet need in the healthcare sector.